Researchers at The Cleveland Clinic Lerner College of Medicine recently explored the development of a psoriasiform rash in patients with inflammatory bowel disease or rheumatoid arthritis who were treated with TNF-ɑ inhibitors. Learn what they discovered in this article.
David Ozeri, M.D.
Researchers recently performed a control trial to test the efficacy of BMS-986165 a potent TYK2 inhibitor. Here's what they found.
A recent study suggests that patients suffering from psoriasis and psoriatic arthritis may have an increased risk of developing autoimmune thyroid disease.
Increased mortality described in the first study to review all-cause mortality and cause-specific mortality in patients with psoriasis.
Doctors should be vigilant about recognizing the signs and symptoms of patients who may develop ILD in order to prevent catastrophic complications, such as respiratory failure.
Having psoriasis gives a patient a 1.75-fold increased odds of developing ulcerative colitis and a 1.70-fold increased odds of developing Crohn's disease.